Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Genedrive ( (GB:GDR) ) has shared an announcement.
Genedrive plc said University Hospitals Sussex NHS Foundation Trust has moved its Genedrive MT-RNR1 ID kit for preventing antibiotic-induced hearing loss in neonatal intensive care units to a Business as Usual clinical service from 1 May 2026. The transition at the Trevor Mann Baby Unit, an early adopter and participant in the PALOH-UK real-world evidence programme, underscores growing clinical integration after the test identified nearly 40 UK babies with the MT-RNR1 variant, enabling alternative antibiotic use and reducing lifelong hearing-loss risk.
Management described the move as a key milestone for wider UK uptake, noting active talks with other PALOH-UK hospitals to embed the MT-RNR1 assay into routine care as central programme funding from the Office for Life Sciences and NIHR winds down by June 2026. The shift towards hospital-funded adoption ahead of final NICE guidance expected around July 2027 signals potential revenue visibility for Genedrive and highlights how real-world evidence is driving precision pharmacogenetic testing deeper into standard NHS practice.
Spark’s Take on GDR Stock
According to Spark, TipRanks’ AI Analyst, GDR is a Neutral.
The score is held back primarily by weak financial performance—large ongoing losses, sustained cash burn, and a shrinking equity base despite minimal debt. Technicals are moderately supportive with price above key moving averages and positive MACD, but elevated RSI signals near-term overheating risk. Valuation remains challenging due to negative earnings (negative P/E).
To see Spark’s full report on GDR stock, click here.
More about Genedrive
Genedrive plc is a UK-based, commercial-stage pharmacogenetic testing company specialising in rapid, point-of-care diagnostics that guide safer and more effective drug prescribing in emergency and acute care settings. Its CE-IVD approved and NICE-recommended assays include the CYP2C19 test for tailoring stroke therapy and the MT-RNR1 test to prevent antibiotic-induced hearing loss in newborns, underpinning a strategy to scale precision diagnostics in the NHS and internationally.
Average Trading Volume: 5,073,774
Technical Sentiment Signal: Strong Sell
Current Market Cap: £15.25M
See more insights into GDR stock on TipRanks’ Stock Analysis page.